Matt Larew

Stock Analyst at William Blair

(0.37)
# 4,288
Out of 5,141 analysts
15
Total ratings
30%
Success rate
-23.96%
Average return

Stocks Rated by Matt Larew

Waters
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $333.33
Upside: -
Charles River Laboratories International
Oct 6, 2025
Upgrades: Outperform
Price Target: n/a
Current: $168.92
Upside: -
Thermo Fisher Scientific
Aug 19, 2025
Initiates: Outperform
Price Target: n/a
Current: $510.93
Upside: -
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.74
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.10
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $9.22
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $145.05
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $57.52
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.03
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $8.16
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $48.59
Upside: -